The article reviews current options for the treatment of infections caused by carbapenemase-producing Enterobacterales, including the role of aztreonam/avibactam.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Role of aztreonam/avibactam in antibiotic therapy].
Klin Mikrobiol Infekc Lek
September 2024
Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Olomouc University Hospital, Czech Republic, e-mail:
The article reviews current options for the treatment of infections caused by carbapenemase-producing Enterobacterales, including the role of aztreonam/avibactam.
View Article and Find Full Text PDFIn vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases.
J Glob Antimicrob Resist
February 2025
Department of Microbiology, Fujita Health University School of Medicine, Aichi, Japan; Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan; Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, PA, USA; Center for Infectious Disease Research, Fujita Health University, Aichi, Japan. Electronic address:
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options. Pathogens producing metallo-β-lactamase are particularly problematic since they are not inhibited by conventional β-lactamase inhibitors. Herein, we assess the in vitro activity of aztreonam in combination with relebactam against a collection carbapenemase producing organisms, including strains producing both serine‑β-lactamase and IMP-type metallo-β-lactamase that are commonly encountered in Japan.
View Article and Find Full Text PDFCharacterization of Metallo β-Lactamase Producing Isolates with Susceptibility to the Aztreonam/Avibactam Combination.
Antibiotics (Basel)
December 2024
Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Metallo-β-lactamases (MBLs) in and other Gram-negative organisms pose significant public health threats due to their association with multidrug resistance (MDR). Although aztreonam (AZT) can target MBL-producing organisms, its efficacy is compromised in organisms expressing additional β-lactamases that inactivate it. Combining AZT with the β-lactamase inhibitor avibactam (AVI) may restore its activity against MBL-producing isolates.
View Article and Find Full Text PDFIn vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.
Eur J Clin Microbiol Infect Dis
December 2024
Microbiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata Di Verona, Verona, Italy.
Article Synopsis
- The study investigates how KPC variants of Klebsiella pneumoniae develop resistance to new β-lactam/β-lactamase inhibitor combinations (βL/βLICs) among patients treated with these antibiotics.
- Researchers conducted a case series involving four patients with bloodstream infections linked to KPC-Kp, noting that most had underlying health issues and experienced severe complications.
- Resistance mutations were identified in the KPC genes following treatment, emphasizing that the use of novel βL/βLICs can lead to the emergence of resistant strains, particularly against ceftazidime/avibactam.
Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides against VIM-producing .
Microbiol Spectr
October 2024
College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
Metallo-beta-lactamase (MBL)-producing carbapenem-resistant (CRE) infections continue to pose a serious threat to healthcare. Due to their unique active site, MBLs evade the activity of many novel beta-lactam/beta-lactamase inhibitor combinations, which have been specifically targeted toward those carbapenemases with serine active sites. Furthermore, resistance to most, if not all, other clinically relevant antimicrobial classes leaves few reliable therapeutic options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!